StopUMTS Logo
how to get rid of moles 
Zoeken
   
Voorlichting
05/02/18Voorlichting voor wie nie
23/01/18Meetspecialisten, afsc
Artikelen
18/02/18Can Cell Tower Radiation
14/02/18Vaccins: een veiligheidsv
11/02/18Autisme: New CDC Statisti
09/02/18De Volkskrant: Leven met
08/02/18Skepsis en de Vereniging
06/02/18How 5G Will Kill the Bird
Berichten Nederland
16/02/18Blogs Hugo Schooneveld (v
15/02/18Mogelijk toch 5G-netwerk
15/02/185G: Nederlandse overheid
09/02/18Haarlemmers stappen naar
06/02/18Foto's: Ziek van Straling
Berichten België
14/02/18Stralingsoverlast door ze
13/02/18Strenge stralingsnormen b
Berichten Internationaal
17/02/1818 child smart watches fa
16/02/18Duitsland: Tewlekom - waa
15/02/18USA: SpaceX mag van FCC-v
15/02/18Frankrijk verbiedt telefo
Ervaringen | Appellen/oproepen
09/02/18Burostoel met smart activ
15/01/18Ziekmakende ervaringen me
12/01/18Soms is tinnitus geen tin
Onderzoeken
15/02/18Effects of electromagneti
07/02/18NTP: High Exposure to Rad
02/02/18Occupational exposure to
Veel gestelde vragen
13/05/17Vakantie? Witte zo
10/07/16Zeven veel gestelde vrage
Juridische informatie
23/01/18Reeks publicaties op juri
23/01/18Juridisch advies en begel
19/01/18Afspraken voor beterere t
Oproepen
17/03/18Cursus straling meten voo
03/03/18Lezing: Wat doen elektrom
31/01/18Witte zone in Getelo (Ned
Folders
10/09/17Brochures, folders, websi
29/04/16USA: Meer dan 50 tips voo
Briefwisselingen | Archief: 2008, 2005
20/02/18Voorbeeldbrief Gemeentera
11/02/18Open brief aan KPN na ond
Illustraties
 Algemeen
 Fotoalbum zendmasten
 Wetenschappelijke illustraties
USA/Brazilië: Behandeling leverkanker met zeer zwakke elektromagnetische velden.    
Ga naar overzicht berichten in: Onderzoeken

USA/Brazilië: Behandeling leverkanker met zeer zwakke elektromagnetische velden.
dinsdag, 16 augustus 2011 - Dossier: Algemeen


Gerelateerd artikel: Berichten%20Internationaal/5991

Bron: British Journal of Cancer 9 August 2011; doi: 10.1038/bjc.2011.292

Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields

F P Costa 1, A C de Oliveira 1, R Meirelles 1, M C C Machado 1, T Zanesco 1, R Surjan 1,
M C Chammas 2, M de Souza Rocha 2,
D Morgan 3,
A Cantor 4,
J Zimmerman 5,
I Brezovich 6,
N Kuster 7,
A Barbault 8 and
B Pasche 5

1.
Department of Transplantation and Liver Surgery, Hospital das Clínicas da Faculdade de Medicina, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, 255, São Paulo 05403-000, Brazil

2.
Department of Radiology, Hospital das Clínicas, University of São Paulo, São Paulo 05403-000, Brazil

3.
Department of Radiology, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA

4.
Biostatistics and Bioinformatics Shared Facility, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA

5.
Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, 1802 6th Ave South, NP 2566, Birmingham, AL 35294-3300, USA

6.
Department of Radiation Oncology, The University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA

7.
IT'IS Foundation, Swiss Federal Institute of Technology, Zurich, Switzerland

8.
Rue de Verdun 20, Colmar 68000, France

Correspondence:
Dr FP Costa, E-mail: fredericoperegocosta@gmail.com;
Dr B Pasche, E-mail: Boris.Pasche@ccc.uab.edu

Abstract
Background:

Therapeutic options for patients with advanced hepatocellular carcinoma (HCC) are limited. There is emerging evidence that the growth of cancer cells may be altered by very low levels of electromagnetic fields modulated at specific frequencies.

Methods:

A single-group, open-label, phase I/II study was performed to assess the safety and effectiveness of the intrabuccal administration of very low levels of electromagnetic fields amplitude modulated at HCC-specific frequencies in 41 patients with advanced HCC and limited therapeutic options. Three-daily 60-min outpatient treatments were administered until disease progression or death. Imaging studies were performed every 8 weeks. The primary efficacy end point was progression-free survival greater than or equal to6 months. Secondary efficacy end points were progression-free survival and overall survival.

Results:
Treatment was well tolerated and there were no NCI grade 2, 3 or 4 toxicities. In all, 14 patients (34.1%) had stable disease for more than 6 months. Median progression-free survival was 4.4 months (95% CI 2.1–5.3) and median overall survival was 6.7 months (95% CI 3.0–10.2). There were three partial and one near complete responses.

Conclusion:
Treatment with intrabuccally administered amplitude-modulated electromagnetic fields is safe, well tolerated, and shows evidence of antitumour effects in patients with advanced HCC.


Voor het originele abstract zie:
www.nature.com/bjc/journal/vaop/ncurrent/abs/bjc2011292a.html .


Ga terug naar het hoofdmenu
Afdrukken | Vragen | RSS | Disclaimer